Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cel-Sci Corporation Common Stock
(NY:
CVM
)
0.3990
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EST, Feb 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cel-Sci Corporation Common Stock
< Previous
1
2
3
Next >
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
August 19, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
August 15, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
August 08, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
July 14, 2022
From
CEL-SCI Corporation
Via
Business Wire
TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Shares Replays of 2022 LD Micro Invitational Company Presentations
June 16, 2022
Via
Investor Brand Network
CEL-SCI Corporation to Present at LD Micro Invitational
June 08, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
June 07, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Publication of ASCO 2022 Abstracts
May 27, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
May 16, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
April 22, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
February 14, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
December 22, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
October 22, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation (NYSE:CVM) Investor Investigation over Potential Wrongdoing
September 07, 2021
San Diego, CA -- (SBWIRE) -- 09/07/2021 -- Certain directors of CEL-SCI Corporation are under investigation over potential breaches of fiduciary duties.
Via
SBWire
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
August 16, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation (NYSE:CVM) Shareholder Notice: Investigation over Possible Violations of Securities Laws
July 13, 2021
San Diego, CA -- (SBWIRE) -- 07/13/2021 -- CEL-SCI Corporation is under investigation concerning potential securities laws violations in connection with certain financial statements.
Via
SBWire
CEL-SCI Corporation Issues Letter to Shareholders
July 07, 2021
From
CEL-SCI Corporation
Via
Business Wire
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
July 02, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
June 30, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
June 28, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
June 25, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
June 11, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
June 08, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Bought Deal Offering
June 08, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results
May 18, 2021
From
CEL-SCI Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.